FDA-Approved CGRP Antibodies for Migraine Prevention
Three FDA-approved monoclonal antibodies targeting CGRP provide effective migraine prevention with a new mechanism of action.
Quick Facts
What This Study Found
Three CGRP-targeting monoclonal antibodies are FDA-approved for migraine prevention, reducing attack frequency through a targeted mechanism not available with older drugs.
Key Numbers
39M Americans; 1 in 7 ages 15-49; 3x more in women; 3 FDA-approved mAbs
How They Did This
Review of clinical trial data and FDA-approved indications for erenumab, fremanezumab, and galcanezumab.
Why This Research Matters
Migraine affects 1 in 7 people ages 15-49 and is 3 times more common in women. These first-in-class targeted preventive medications fill a critical gap for patients who couldn't tolerate existing treatments.
The Bigger Picture
CGRP antibodies represent a paradigm shift — the first medications designed specifically for migraine prevention based on understanding of migraine neurobiology.
What This Study Doesn't Tell Us
Brief review without detailed comparative efficacy data. Long-term safety beyond trial durations is still being monitored.
Questions This Raises
- ?How do the three CGRP antibodies compare in efficacy and side effects?
- ?What is the optimal duration of treatment?
- ?Can CGRP antibodies be combined with other preventives?
Trust & Context
- Key Stat:
- 39 million Americans affected by migraine, with 3 new CGRP-targeting antibodies now available
- Evidence Grade:
- Review of FDA-approved medications backed by phase 3 clinical trial data. Strong evidence base.
- Study Age:
- Published in 2020. Since then, additional CGRP-targeting medications have received approval.
- Original Title:
- Medications Approved for Preventing Migraine Headaches.
- Published In:
- The American journal of medicine, 133(6), 664-667 (2020)
- Authors:
- Spindler, Brittany L, Ryan, Melody
- Database ID:
- RPEP-05148
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do CGRP antibodies prevent migraines?
These antibodies block CGRP, a neuropeptide central to migraine. Erenumab blocks the CGRP receptor, while fremanezumab and galcanezumab bind CGRP itself, preventing it from activating the receptor.
Who should consider CGRP antibodies?
They are indicated for adults with episodic or chronic migraine, particularly those who haven't responded to or couldn't tolerate existing preventive medications.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05148APA
Spindler, Brittany L; Ryan, Melody. (2020). Medications Approved for Preventing Migraine Headaches.. The American journal of medicine, 133(6), 664-667. https://doi.org/10.1016/j.amjmed.2020.01.031
MLA
Spindler, Brittany L, et al. "Medications Approved for Preventing Migraine Headaches.." The American journal of medicine, 2020. https://doi.org/10.1016/j.amjmed.2020.01.031
RethinkPeptides
RethinkPeptides Research Database. "Medications Approved for Preventing Migraine Headaches." RPEP-05148. Retrieved from https://rethinkpeptides.com/research/spindler-2020-medications-approved-for-preventing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.